The accelerated reshuffle of the pharmaceutical market is affecting a large number of enterprises!

[Pharmaceutical Network Market Analysis] In recent years, under the environment of new medical reform and normalization of centralized procurement, the reshuffle of the pharmaceutical market has intensified.
Since 2022, a large number of pharmaceutical companies have stopped production and cancelled their certificates and no longer operate
.

In addition, since the beginning of this year, a large number of pharmaceutical companies have been punished for non-compliant operations
.

 The accelerated reshuffle of the pharmaceutical market is affecting a large number of enterprises! (Photo source: Pharmaceutical Network) For example, recently, the Chongqing Municipal Food and Drug Administration released information on administrative law enforcement cases.
A pharmaceutical company in Chongqing was given a warning, confiscated illegal property, and confiscation of illegal gains for producing and selling inferior medicines; March 2 , Hubei Provincial Food and Drug Administration released an administrative penalty information, and four pharmaceutical companies in Hubei were punished for producing and selling inferior drugs
.

It can be seen from the above that in the current pharmaceutical environment, the survival challenges of pharmaceutical companies have become more and more serious, and they not only need to face competition between enterprises, but also face stricter supervision
.

In this context, pharmaceutical companies need to actively make strategic layouts, operate in compliance, and accelerate transformation and upgrading in order to go further
.

It is understood that in fact, in recent years, local pharmaceutical companies are accelerating innovation in order to cope with more and more changes in the pharmaceutical industry
.

At present, the investment of many pharmaceutical companies in innovative research and development has continued to rise
.

Among them, the R&D investment of large-scale enterprises has an average annual growth rate of about 8%.
For example, in 2020, the R&D expenses of listed companies will account for more than 6% of sales revenue
.

In addition, the R&D investment of innovative drug industry chain companies in the third quarter of 2021 has also increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.

 　　Of course, in addition to accelerating transformation in research and development, pharmaceutical companies are also accelerating their upgrades in pharmaceutical production
.

At present, in order to expand production and develop higher quality, many pharmaceutical companies are building new manufacturing bases and upgrading and using more efficient and energy-saving pharmaceutical equipment
.

 　　For example, Sanxin Medical recently announced that in order to further expand the market influence of the company's hemodialysis series products and meet market demand, the company urgently needs to increase the production capacity of hemodialysis series products, so it plans to use its own funds and bank loans of 568 million yuan to build a new building "Project of R&D and Production Base of Hemodialysis Series Products"
.

According to reports, the project will build production workshops, R&D test buildings, science and technology innovation buildings and supporting facilities for production and living, and purchase corresponding production equipment
.

 　　Last year, Hongdou Group's anti-tumor high-end complex preparation smart factory project with a total investment of 520 million yuan has also officially started
.

This project is an important manifestation of the Group's accelerated promotion of intelligent and high-end development, and is also a key project to enhance the company's international competitiveness
.

It is estimated that the annual output of anti-tumor injections will reach 20 million bottles, and the annual output of anti-tumor solid preparations will reach 100 million tablets, with an output value of more than 1.
5 billion yuan and an annual profit of 300 million yuan
.

 　　From the above point of view, the industry generally believes that due to the reshuffle of the pharmaceutical market, pharmaceutical companies are accelerating their transformation and upgrading
.

In this context, the pharmaceutical equipment industry, which is closely related to pharmaceutical production, will also usher in new opportunities for development
.

In fact, the role of pharmaceutical equipment in the pharmaceutical industry is self-evident.
It is the equipment that is in close contact with medicines and is also a key link in the production of medicines
.

At a time when drug safety has been given multiple concerns and industry standards have been gradually improved and stricter, pharmaceutical equipment will play a crucial role
.

Therefore, it is also necessary for pharmaceutical machine companies to invest more energy in the production and innovative research and development of pharmaceutical equipment
.

 　　According to the author's understanding, many pharmaceutical equipment companies have begun to innovate and integrate the core parts manufacturing process into product research and development.
At the same time as the demand, it is also further helping pharmaceutical companies to reduce costs and increase efficiency
.

It is expected in the industry that with the "cooperation war" in the pharmaceutical equipment industry, the transformation and upgrading of pharmaceutical companies will be accelerated, and the market competitiveness will continue to increase
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.